Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.
Company Details
- Employees
- 22
- Founded
- -
- Address
- Wagistrasse 14, Bio-Technopark Schlieren-Zurich,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mabylon.com
- HQ
- Schlieren
Mabylon Ag Questions
Mabylon Ag's website is mabylon.com
Mabylon Ag's LinkedIn profile is https://ch.linkedin.com/company/mabylon
Mabylon Ag has
22 employees.
View email and phone details for 22
employees at Mabylon Ag.
Mabylon Ag's industry is
Biotechnology Research
Mabylon Ag's top competitors are
Biognosys,
Numab Therapeutics Ag,
Neurimmune Ag,
Athebio Ag,
Immunos Therapeutics Ag,
Molecular Partners,
Araris Biotech Ag,
Cdr-Life Inc.,
Cutiss Ag,
Memo Therapeutics Ag.
Mabylon Ag's categories are Biotechnology Research
Mabylon Ag's founding year is 2015
